technology+therapeutics

The health agency urged Regeneron, which holds the patent, to lower the drug’s price and work on equitable distribution worldwide.

Members of Congress want to ensure that reports from the national academies, chartered in 1863 to provide Congress with expert scientific advice, are widely accepted as independent and free from special-interest or financial influence.

Biosimilars are cheaper versions of biologic drugs made from living organisms.

Tezepelumab for Severe Asthma

CNBC's Meg Tirrell joins Shep Smith to discuss Americans' attitude toward vaccines as well as treatments like monoclonal antibodies.

Such treatments are extraordinarily promising and costly. Will the Biden administration commit to spending that could speed clinical trial results?

Elevated by social media and right-wing pundits and politicians, ivermectin is not recommended by either the FDA or its manufacturer to treat covid-19.

At issue is the accelerated approval program created nearly three decades ago to hasten availability of drugs for serious conditions with unmet medical needs.

As Congress reconvenes this month to resolve a $3.5 trillion budget package, Democrats are focused on enacting sweeping legislation that would allow the government to negotiate prices for prescription drugs.

NICE has updated its guidelines on the management of type 2 diabetes, recommending wider use of SGLT2 inhibitors in those with or at high-risk of cardiovascular disease (CVD).

GSK’s Emma Walmsley is seeking to survive a challenge from Elliott Investment Management, the activist that no CEO wants to hear from.

QALY as a measurement has received a lot of criticism. It's been criticized in concept or in the specifics of how it's defined or used.

A baby who received the world's most expensive drug four weeks ago has made "huge" progress, his parents said.

The health service will make the new treatment, inclisiran, available to 300,000 patients with high cholesterol and a history of cardiovascular disease over the next three years.

A panel of regulators overseeing the implementation of several big data projects within the EU medicines network has given details of real-world evidence integration pilots to be undertaken next year.